pro portion of cases. Research is aimed at developing novel treatments using neuroprotective and regenerative strategies.
SCs can potentially be used for both neuroprotection and cell replacement. Intravitreal delivery of neurotrophic factors slows down photoreceptor degeneration in rodent models of RP, RGC loss in glaucoma models, and optic nerve and optic tract trauma, but the eff ect may be temporary. Slow-release preparations and gene therapy approaches used to induce retinal cells to secrete neurotrophic factors are two ways to induce longer-term eff ects. A third option is to use SCs as long-term delivery agents, possibly encapsulated in a device, because many SCs either secrete neurotrophins naturally or can be genetically engineered to do so [15] [16] [17] . SCs can be injected into the eye through the intravitreal or subretinal technique [18] [19] [20] [21] .
Progress has also been made in the fi eld of photoreceptor, RPE, and RGC replacement by SCs and progenitor cells, although long-term restoration of visual function has not been confi rmed. Th e recent discoveries that human fi broblasts can be 'reprogrammed' to behave like embryonic SCs and that adult eyes harbor retinal progenitor cells (RPCs) also increase the potential availability of SCs for trans plantation, including autolo gous transplantation, and stimulate intrinsic 'self-regeneration' , which could poten tially overcome a lot of the problems associated with non-autologous transplan tation in humans [15] .
Potential sources of stem cells for cell therapy in retinal diseases
Bone marrow-derived stem cells BM-derived SCs have been proposed as a potential source of cells for regenerative medicine [9, 22] . Th is is based on the assumption that HSCs isolated from BM are plastic and are able to 'transdiff erentiate' into tissuecommitted SCs for other organs (for example, heart, liver, or brain). Unfortunately, the concept of SC plasticity was not confi rmed in recent studies, and previously encourag ing data demonstrating this phenomenon in vitro could be explained by a phenomenon of cell fusion or, as believed by our group, by the presence of heterogeneous populations of SCs in BM [23] . Th e identifi cation of very small, embryonic-like SCs in BM supports the notion that this tissue contains a population of primitive SCs, which, if transplanted together with HSCs, would be able to regenerate damaged tissues in certain experimental settings. Cells from BM are easily and safely aspirated. After administration of local anesthesia, about 10 mL of the BM is aspirated from the iliac crest by means of a sterile BM aspiration needle; subsequently, mononuclear BM-derived SCs are separated by using the Ficoll density separation method [3, 18] .
SC-based therapy has been tested in animal models for several diseases, including neurodegenerative disorders such as Parkinson disease, spinal cord injury, and multiple sclerosis. Th e replacement of lost neurons that are not physiologically replaced is pivotal for therapeutic success. In the eye, degeneration of neural cells in the retina is a hallmark of widespread ocular diseases such as AMD and RP. In these cases, the photoreceptor loss that occurs as a primary event (as in RP) or secondary to loss of RPE (as in AMD) leads to blindness [3, 9] .
BM is an ideal tissue for studying SCs because of its accessibility and because proliferative dose responses of BM-derived SCs can be readily investigated. Furthermore, there are a number of well-defi ned mouse models and cell surface markers that allow eff ective studies of hematopoiesis in healthy and injured mice. Because of these characteristics and the experience of BM transplantation in the treatment of hematological cancers, BM-derived SCs have also become an important tool in regenerative medicine. Th e BM harbors at least two distinct SC populations: HSCs and mesen chymal stem cells (MSCs) [24, 25] .
Hematopoietic stem cells
HSCs are multipotent SCs that give rise to all of the blood cell types, including myeloid lineages (monocytes, macrophages, neutrophils, basophils, eosinophils, eryth rocytes, megakaryocytes/platelets, and dendritic cells) and lymphoid lineages (T cells, B cells, and natural killer cells). HSCs are found in adult BM in, for example, femurs, hips, ribs, the sternum, and other bones. Cells can be obtained directly from the hip by using a needle and syringe (Figure 1 ) or from the blood after pre treatment with cytokines, such as G-CSFs (granulocyte colonystimulating factors), that induce cells to be released from the BM compartment. Other sources for clinical and scientifi c use include UCB and placenta [23, 24] .
In reference to phenotype, HSCs are identifi ed by their small size, lack of lineage markers, low staining (side population) by vital dyes such as rhodamine 123 (rhodamine-dull, also called rholo) or Hoechst 33342, and presence of various surface antigenic markers, many of which belong to the cluster of diff erentiation (CD) series (CD34, CD38, CD90, CD133, CD105, and CD45) and also c-kit and SC factor receptor [26] [27] [28] [29] [30] [31] . Otani and colleagues [16] demonstrated that, whenever a fraction of mouse or human adult BM-derived SCs (lineage-negative hematopoietic stem cells, or Lin-HSCs) containing endothelial precursors stabilizes and rescues retinal blood vessels that would ordinarily completely degenerate, a dramatic neurotrophic rescue eff ect is also observed. Retinal nuclear layers are preserved in two mouse models of retinal degeneration, rd1 and rd10, and detectable, albeit severely abnormal, electroretinogram recordings are observed in rescued mice at times when they are never observed in control-treated or untreated eyes. Th e normal mouse retina consists predominantly of rods, but the rescued cells after treatment with Lin-HSCs are nearly all cones. Microarray analysis of rescued retinas demonstrates signifi cant upregulation of many antiapoptotic genes, including small heat shock proteins and transcription factors.
Some reports have demonstrated the clinical feasibility of the intravitreal administration of autologous bone marrow-derived mononuclear cells (ABMCs) in patients with advanced degenerative retinopathies [32, 33] . More recently, our group conducted a prospective, phase I, non-randomized, open-label study that included three patients with RP and two patients with cone-rod dystrophy and an Early Treatment Diabetic Retinopathy Study best-corrected visual acuity of 20/200 or worse [34] . Evaluations such as best-corrected visual acuity, fullfi eld electroretinography, kinetic visual fi eld (Goldman), fl uorescein and indo cyanine green angiography, and optical coherence tomography were performed at baseline and 1, 7, 13, 18, 22, and 40 weeks after intravitreal injection of 10 × 10 6 ABMCs (0.1 mL) into one study eye of each patient. No adverse event associated with the injection was observed. A 1-line improvement in bestcorrected visual acuity was measured in four patients 1 week after injection and was maintained throughout follow-up. Th ree patients showed undetectable electroretinography responses at all study visits, whereas one patient demonstrated residual res ponses for darkadapted standard fl ash stimulus (a wave amplitude of approximately 35 mV), which remained recordable throughout follow-up, and one patient showed a small response (a wave amplitude of approximately 20 mV) recordable only at weeks 7, 13, 22, and 40. Visual fi elds showed no reduction (with a Goldman Standard V5e stimulus) for any patient at any visit. No other changes were observed on optical coherence tomography or fl uorescein and indocyanine green angiograms. We conclude that intravitreal injection of ABMCs in eyes with advanced RP or cone-rod dystrophy was associated with no detectable structural or functional toxicity over a period of 10 months [34] .
Mesenchymal stem cells
MSCs are progenitors of all connective tissue cells. In adults of multiple vertebrate species, MSCs have been isolated from BM and other tissues, expanded in culture, and diff erentiated into several tissue-forming cells such as bone, cartilage, fat, muscle, tendon, liver, kidney, heart, and even brain cells.
According to the International Society for Cellular Th erapy [35] , there are three minimum requirements for a population of cells to be classifi ed as MSCs. Th e fi rst is that MSCs, unlike BM-derived hematopoietic cells, are isolated from a population of mononuclear cells on the basis of their selective adherence to the surface of the plastic of culture dishes; a disadvantage of this method of identifi cation is the possible contamination by hematopoietic cells and cellular heterogeneity with respect to the potential for diff erentiation. Second, CD105, CD73, and CD90 must be present and CD34, CD45, CD14 or CD11b, CD79, or CD19 and HLA-DR must not be expressed in more than 95% of the cells in culture. Finally, the cells can be diff erentiated into bone, fat, and cartilage [36] .
A number of studies have shown that BM-derived MSCs can diff erentiate into cells expressing photoreceptor proteins when injected into the subretinal space [37, 38] . Interestingly, it has been suggested that rat MSCs can be made to express photopigment (rhodopsin) in vitro simply by adding epidermal growth factor to the culture media [39] . Additionally, although other retinarelevant cell types have been engineered, a number of studies have shown that BM-or adipose tissue-derived MSCs are converted to RPE cells [39] [40] [41] . As with work on other neuronal phenotypes, however, there has now been a reassessment of the ability of MSCs to diff erentiate into functionally useful retinal cells. Some studies have shown that transplanted BM-derived MSCs do not diff erentiate into neural retinal cells [42] . In an in vitro rat retina-explant model, untreated MSCs seemed to transdiff erentiate into microglia109 in a way reminiscent of earlier work on MSC transplants in other neurological tissue [43] . Some limited improvement was seen with pre-treatment with brain-derived neurotrophic factor (BDNF), nerve growth factor, and basic fi broblast growth factor (bFGF) in terms of morphological diff er entiation into retinal neurons and expression of NF200, GFAP, PKC-alpha, and recoverin, but these cells did not express rhodopsin [44] .
In an ischemic retina rodent model, MSCs injected into the vitreous cavity have been shown to mature (with expression of neuron-specifi c enolase and neurofi lament) and secrete ciliary neurotrophic factor (CNTF), bFGF, and BDNF for at least 4 weeks [45] . Animal studies have also demonstrated that subretinal transplantation of MSCs delays retinal degeneration and preserves retinal function through a trophic response [46] . UCB-derived MSCs have also been shown to be neuroprotective of rat ganglion cells [47] . Very recently, the intravenous adminis tration of BM-derived MSCs was shown to prevent photoreceptor loss and preserve visual function in the Royal College of Surgeons (RCS) rat model of RP [48] .
A role for genetically modifi ed MSCs may emerge in the treatment of subretinal neovascularization. It has been shown that BM-derived MSCs accumulate around subretinal membranes induced by retinal laser burns. Intravenous injection of mouse BM-derived MSCs genetically engineered to secrete pigment epithelium-derived factor resulted in smaller neovascular complexes [49] .
Induced pluripotent stem cells
Current methods of producing SCs from adult somatic cells off er an alternative cell source for transplantation. Induced pluripotent stem cells (iPSCs) are morphologically identical to embryonic SCs, display similar gene expression profi les and epigenetic status, and have the potential to form any cell in the body [45, 50] . Th ese cells have been employed to generate cells for the treatment of various diseases, including diabetes, cardio vascular disease, sickle cell anemia, Parkinson disease, and hemophilia [51] [52] [53] [54] [55] . Meyer and colleagues [56] recently showed that iPSCs can diff erentiate into retinal cell types, whereas a paper by Buchholz and colleagues [57] showed that human iPSCs can be diff erentiated into retinal pigment epithelial cells that display functionality in vitro.
Carr and colleagues [58] demonstrated that iPSCs can be diff erentiated into functional iPSC RPE cells and that transplantation of these cells can facilitate the short-term maintenance of photoreceptors through phagocytosis of photoreceptor outer segments. Long-term visual function is maintained in this model of retinal disease even though the xenografted cells are eventually lost, suggesting a secondary protective host cellular response. Zhao and colleagues [59] showed that abnormal gene expression in some cells diff erentiated from iPSCs can induce T cell-dependent immune response in syngeneic recipients. Th erefore, the immunogenicity of therapeutically valuable cells derived from patient-specifi c iPSCs should be evaluated before any clinical application of these autologous cells into the patients.
Owing to viral insertions of pluripotency genes, this particular line of iPSC RPE cells cannot be used as a direct therapy, but recent advances in iPSC cell re programming technology, including the use of small molecules [60] , piggyBac transposition [61, 62] , nonintegrating episomal vectors [63] , and manipulation of endogenous transcription factors [64] , should eliminate the risks associated with the integration of SC genes into the genome. Furthermore, the fi nding that blood cells can be used to derive iPSCs [65] may remove the need for the invasive biopsies required to collect somatic cells and accelerate the ethical production of SC-derived tissue for therapeutic use.
Human embryonic stem cells
Th e human embryonic stem cell (hESC) is defi ned as a cell that can both renew itself by repeated division and diff erentiate into any one of the 200 or more adult cell types in the human body. An hESC arises from the eightcell stage morula. Outside of normal development, hESCs have been diff erentiated in vitro into neural cell types and even pigmented epithelium, although controlling their diff erentiation has proven challenging. Several hESC lines exist and are supported by public research funds. Th e use of hESCs has signifi cant limitations, including ethical issues, and a risk of teratoma formation, but the chief problem is that we are still struggling to understand the developmental cues that diff erentiate hESCs into the specifi c adult cell types required to repair damaged tissues [66] .
Nistor and colleagues [67] showed, for the fi rst time, that three-dimensional early retinal progenitor tissue constructs can be derived from hESCs. Th ree-dimensional tissue constructs were developed by culturing hESCderived neural retinal progenitors in a matrix on top of hESC-derived RPE cells in a cell culture insert. An osmolarity gradient maintained the nutrition of the three-dimensional cell constructs. Cross-sections through hESC-derived tissue constructs were character ized by immunohistochemistry for various transcription factors and cell markers. Tissue constructs derived from hESCs expressed transcription factors characteristic of retinal development, such as pax6, Otx2, Chx10, retinal RAX, Brn3b (necessary for diff erentiation of RGCs), and crx and nrl (which have a role in photoreceptor development). Many cells expressed neuronal markers, including nestin, beta-tubulin, and microtubule-associated protein.
Assessments of safety and effi cacy are crucial before hESC therapies can move into the clinic. Two important early potential hESC applications are the use of RPE cells for the treatment of AMD and Stargardt disease, an untreatable form of macular dystrophy that leads to early-onset blindness. Long-term safety and function of RPE from hESCs in preclinical models of macular degeneration were demonstrated by Lu and colleagues [68] . Th ey showed long-term functional rescue by using hESC-derived RPE in both RCS rats and Elov14 mice, which are animal models of retinal degeneration and Stargardt disease, respectively. Good manufacturing practice-compliant hESC RPE cells survived subretinal transplantation in RCS rats for prolonged periods (>220 days). Th e cells sustained visual function and photoreceptor integrity in a dose-dependent fashion without teratoma formation or untoward pathological reactions.
Near-normal functional measurements were recorded at survival of greater than 60 days in RCS rats. To further address safety concerns, a good laboratory practicecompliant study was carried out in the NIH III immunedefi cient mouse model. Long-term data (spanning the life of the animals) showed no gross or microscopic evidence of teratoma/tumor formation after subretinal hESC RPE cell transplantation. Th ese results suggest that hESCs could serve as a potentially safe and inexhaustible source of RPE cells for the effi cacious treatment of a range of retinal degenerative diseases.
In 2010, the US Food and Drug Administration granted orphan drug designation to RPE cells for Advanced Cell Technology, Inc. (Santa Monica, CA, USA) to initiate its phase 1/2 clinical trials using RPE cells derived from hESCs to treat patients with Stargardt macular dystrophy. Moreover, in 2011, the company received a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency for the designation of this product as an orphan medicinal product for the treatment of Stargardt disease [69, 70] .
Retinal progenitor cells
RPCs, considered the active cellular component of fetal retinal transplants, were purifi ed from green fl uorescent protein transgenic mice and trans planted into the degenerating retina of a mature mouse model. Th e transplanted RPCs developed into neurons, including presumptive photoreceptor cells expres sing rhodopsin, opsin, and recoverin. Th e host showed rescue of the outer retina layer cells with integration of donor cells occurring in multiple retinal layers. Th e greatest concentration of integration in the outer retina and, most importantly, recipient mice, demonstrated an improved response to light [71, 72] .
In adults, the neural retina and RPE have overlapping regenerative capacity after injury (for example, in amphibians, injury can activate both retinal and RPE progenitor cells to mediate regeneration and repair).
Table 1. Mechanisms of the paracrine eff ect

Paracrine eff ect Mechanisms
Increased angiogenesis Stem cells produce local signaling molecules that may improve perfusion and enhance angiogenesis to chronically ischemic tissue. Although the particular growth factors contributing to this neovascular eff ect remain to be defi ned, the list includes vascular endothelial growth factor, hepatocyte growth factor, and basic fi broblast growth factor 2 [84, 85] .
Decreased infl ammation Stem cells appear to attenuate infarct size and injury by modulating local infl ammation. When transplanted into injured tissue, the stem cell faces a hostile, nutrient-defi cient, infl ammatory environment and may release substances that limit local infl ammation in order to enhance its survival. Recent studies implicate the release of the anti-infl ammatory cytokine interleukin-10 as playing an integral role in modulating the activity of innate and adaptive immune cells, such as dendritic cells, T cells, and B cells [3, 83, 86] .
Anti-apoptotic and Stem cells in a third pathway promote salvage of tenuous or malfunctioning cell types at the infarct border zone. Injection chemotactic signaling of mesenchymal stem cells (MSCs) into a cryo-induced infarct reduces myocardial scar width 10 weeks later. MSCs appear to activate an anti-apoptosis signaling system at the infarct border zone and this eff ectively protects ischemia-threatened cell types from apoptosis [3, 39, 83] .
Benefi cial remodeling of the Stem cell transplantation alters the extracellular matrix, resulting in a more favorable post-infarct remodeling, extracellular matrix strengthening of the infarct scar, and prevention of deterioration in organ function [3, 83, 87] .
Activation of neighboring Exogenous stem cell transplantation may activate neighboring resident tissue stem cells. These resident stem cells may resident stem cells possess growth factor receptors that can be activated to induce their migration and proliferation and promote both the restoration of dead tissue and the improved function in damaged tissue [3, 26] .
Figure 2. Subretinal technique.
In this technique, a cannula is connected to a 1-mL tuberculin syringe (with a screw plunger) containing balanced salt solution (BSS). The BSS is injected slowly to create a retinotomy, and a small subretinal bleb is raised (A). This procedure minimizes retinal trauma. The cannula is introduced through the retinotomy, and the BSS injection restarts and continues to expand the bleb to the correct volume. A process of gentle retinal massage is used to release the tension in the bleb. The cannula is removed, and a 30-gauge cannula, connected to sterile tubing and syringe preloaded with cells, is introduced in the subretinal space (B).
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Limited damage of amphibian retina activates progenitor cells within the neural retina, presumably retina stem cells (RSCs), to mediate regeneration and repair, whereas extensive damage that destroys most of the neural retina results in the activation of a progenitor cell population within the RPE layer, presumably retinal pigment epithelial SCs, to regenerate both neural retina and RPE [72, 73] . RSCs have been isolated from the edge of the peripheral region of the neurosensory mammalian retina, although questions regarding the true origin of these cells and the ability to self-renew have been raised [74, 75] . More recently, RSCs that demonstrate self-renewal and diff erentiated progeny have been isolated from the posterior neural retina. Of the multiple types of RSCs and RPCs reported, retinal glial Müller cells are the most studied late progenitors that retain competency to produce neuronal lineages, including photoreceptor cells. Müller glial cells actively regenerate damaged retina in lower animals and can be similarly activated in mice by [48] Experimental study in animals Retinitis pigmentosa Tail vein Pluripotent bone marrowderived mesenchymal stem cells Li, et al. [93] Experimental study in animals Rat injured by ischemia/ reperfusion
Intravitreous transplantation Bone marrow mesenchymal stem cells Uteza, et al. [94] Experimental study in animals Photoreceptor cell degeneration in Royal College of Surgeon rats
Intravitreous transplantation Encapsulated fi broblasts
Zhang and Wang [95] Experimental study in animals Light-damaged retinal structure
Subretinal space Bone marrow mesenchymal stem cells Tomita, et al. [96] Experimental study in animals Retinas mechanically injured using a hooked needle
Intravitreous transplantation Bone marrow-derived stem cells Meyer, et al. [97] Experimental study in animals Retinal degeneration Intravitreous transplantation Embryonic stem cells Siqueira, et al. [21] Experimental study in animals Chorioretinal injuries caused by laser red diode 670N-M Intravitreous transplantation Bone marrow-derived stem cells Wang, et al. [98] Experimental study in animals Mice with laser-induced retinal injury
Intravitreous transplantation Bone marrow-derived stem cells Johnson, et al. [99] Experimental study in animals Glaucoma Intravitreous transplantation Bone marrow-derived mesenchymal stem cell Castanheira, et al. [37] Experimental study in animals Rat retinas submitted to laser damage
Intravitreous transplantation Bone marrow-derived mesenchymal stem cell Jonas, et al. [32] Case report Patient with atrophy of the retina and optic nerve
Intravitreous transplantation Bone marrow-derived mononuclear cell transplantation Jonas, et al. [33] Case report Three patients with diabetic retinopathy, age-related macular degeneration, and optic nerve atrophy (glaucoma) [80, 81] . Numerous studies suggest that EPCs re-vascularize ischemic tissues, and recent clinical trials have highlighted the feasibility, safety, and potential therapeutic benefi t of an EPC-based cytotherapy for myocardial infarction. However, there are still discrepancies about the extent to which these cells incorporate into the vasculature and the level to which they restore functionality to damaged tissue. Th ese controversies are caused by an imprecise EPC defi nition as many diff erent cell populations are collectively referred to as EPCs. Recently, Medina and colleagues [82] described a distinct EPC population named outgrowth endothelial cells (OECs). OECs were isolated from adult human peripheral blood and grown on collagen substrate. OECs were able to closely interact with mature endothelial cells through adherens and tight junctions. OECs demon strated de novo tubulogenic potential and fully incor porate into a mature vascular network. Th is is also demon strated in vivo, where OECs directly incorporate into resident ischemic vasculature and signifi cantly decreased avascular areas (P <0.001) when compared with vehicle-injected retinas. Th e authors concluded that OECs have great potential as an alternative treatment for ischemic retinopathies [82] .
Possible mechanisms of retinal function recovery with the use of cell therapy (paracrine eff ect)
SCs may be able to restore the functioning of the retina through two paths: cell replacement (described above with the diff erent types of SC) and rescue therapy (the paracrine eff ect). Th e paracrine eff ect is defi ned as an action exerted by a substance secreted by a cell on local cellular environments. Some cell-to-cell communication requires direct cell-to-cell contact. Some cells can form gap junctions that connect their cytoplasm to the cytoplasm of adjacent cells. In cardiac muscle, gap junctions between adjacent cells allow action potential propagation from the cardiac pacemaker region of the heart to spread and coordinately cause contraction of the heart.
SCs transplanted into injured tissue express paracrine signaling factors, including cytokines, chemokines, and growth factors, which are involved in orchestrating the SC-driven repair process. However, our understanding of the mechanistic basis for SC-mediated paracrine enhance ment of end-organ function remains incomplete. Th e paracrine eff ect can be divided into several mechanisms and may benefi t the treatment of retinal diseases, helping to improve the functioning of cells, as described in Table 1 [3, 26, 39, [83] [84] [85] [86] [87] .
Routes of stem cell transplantation for retinal diseases
Routes that were tested for cell therapy for retinal diseases are systemic administration (intravenous), intravitreal injection, and subretinal injection (Figure 1 ). Figure 2 shows the two subretinal injection techniques: (A) injection of cell suspensions and (B) injection of cells adhered to a matrix (scaff old) [20, [88] [89] [90] .
Conclusions
SCs maintain the balance between somatic cell populations in various tissues and are responsible for organ regeneration. Th e remarkable progress of regenerative medicine in the last few years indicates promise for the use of SCs in the treatment of ophthalmic disorders. Based on the abovementioned mechanisms, experimental and human studies with intravitreal BM-derived SCs have begun (Table 2) [91, 92] . History is starting to be written in this very promising therapeutic fi eld.
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